TR-012001 / Shin Nippon Biomedical Labs - LARVOL DELTA

Results of an exploratory phase II clinical trial of levodopa nasal spray TR-012001 (JSNE 2025) - No abstract available

Clinical • P2 data • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

Results of a Phase I clinical trial of levodopa nasal spray (TR-012001) in healthy Japanese adult males (JSNE 2025) - No abstract available

Clinical • P1 data • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

A Proof-of-concept Study of TR-012001, a Nasal Levodopa, in Patients with Parkinson's Disease with OFF Episodes, Without Dopa Decarboxylase Inhibitor (AAN 2025) - "The study has provided satisfactory safety and tolerability results for TR-012001 (total levodopa 40 mg). The rapid increase in the plasma levodopa concentration and the motor improvement seen in patients with PD supports further clinical development to provide a new ODT option for PD."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Phase II Clinical Study of TR-012001 in Japanese Patients With Parkinson's Disease (clinicaltrials.gov) - P2 | N=12 | Completed | Sponsor: SNLD, Ltd. | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Movement Disorders • Parkinson's Disease

Phase II Clinical Study of TR-012001 in Japanese Patients With Parkinson's Disease (clinicaltrials.gov) - P2 | N=12 | Active, not recruiting | Sponsor: SNLD, Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Movement Disorders • Parkinson's Disease